Table 1:
Patient Characteristics
| Bendamustine + Rituximab (N=113) | Ibrutinib (N=130) | Ibrutinib + Rituximab (N=126) | Total (N=369) | p value | |
|---|---|---|---|---|---|
| Age | 0.671 | ||||
| Median | 71 | 71 | 71 | 71 | |
| Range | (65–86) | (65–87) | (65–86) | (65–87) | |
| Sex | 0.512 | ||||
| Female | 39 (35%) | 37 (28%) | 36 (29%) | 112 (30%) | |
| Male | 74 (65%) | 93 (72%) | 90 (71%) | 257 (70%) | |
| Race | 0.502 | ||||
| White | 103 (91%) | 121 (93%) | 122 (97%) | 346 (94%) | |
| Black or African American | 5 (4%) | 5 (4%) | 2 (2%) | 12 (3%) | |
| Asian | 3 (3%) | 1 (1%) | 0 (0%) | 4 (1%) | |
| American Indian or Alaska Native | 0 (0%) | 0 (0%) | 1 (1%) | 1 (0%) | |
| Not reported: patient refused or not available | 1 (1%) | 2 (2%) | 1 (1%) | 4 (1%) | |
| Unknown: Patient unsure | 1 (1%) | 1 (1%) | 0 (0%) | 2 (1%) | |
| Ethnicity | 0.592 | ||||
| Hispanic or Latino | 2 (2%) | 1 (1%) | 1 (1%) | 4 (1%) | |
| Not Hispanic or Latino | 107 (95%) | 122 (94%) | 122 (97%) | 351 (95%) | |
| Not Reported | 3 (3%) | 6 (5%) | 1 (1%) | 10 (3%) | |
| Unknown | 1 (1%) | 1 (1%) | 2 (2%) | 4 (1%) | |
| Rai Stage | 0.642 | ||||
| Intermediate (Stage I/II) | 49 (43%) | 62 (48%) | 53 (42%) | 164 (44%) | |
| High (Stage III/IV) | 64 (57%) | 68 (52%) | 73 (58%) | 205 (56%) | |
| ECOG Performance Status | 0.162 | ||||
| 0 | 64 (57%) | 65 (50%) | 64 (51%) | 193 (52%) | |
| 1 | 45 (40%) | 63 (48%) | 62 (49%) | 170 (46%) | |
| 2 | 4 (4%) | 2 (2%) | 0 (0%) | 6 (2%) | |
| Zap70 Methylation Status, Central Results | 0.702 | ||||
| <20% | 63 (56%) | 67 (52%) | 71 (56%) | 201 (54%) | |
| >= 20% | 50 (44%) | 63 (48%) | 55 (44%) | 168 (46%) | |
| Presence of del(11q22) or del(17p13), Local Result | 0.782 | ||||
| Yes | 31 (27%) | 35 (27%) | 30 (24%) | 96 (26%) | |
| No | 82 (73%) | 95 (73%) | 96 (76%) | 273 (74%) | |
| Education | 0.802 | ||||
| High school or less or GED | 39 (35%) | 42 (33%) | 44 (35%) | 125 (34%) | |
| Some college | 50 (44%) | 54 (42%) | 47 (38%) | 151 (41%) | |
| Advanced degree | 24 (21%) | 32 (25%) | 34 (27%) | 90 (25%) | |
| Missing | 0 | 2 | 1 | 3 | |
| Marital Status | 0.692 | ||||
| Married/Partnership | 87 (77%) | 101 (78%) | 93 (74%) | 281 (76%) | |
| Other | 26 (23%) | 28 (22%) | 33 (26%) | 87 (24%) | |
| Missing | 0 | 1 | 0 | 1 | |
| Employment Status | 0.842 | ||||
| Employed | 25 (22%) | 28 (22%) | 23 (18%) | 76 (21%) | |
| Retired | 76 (67%) | 87 (68%) | 92 (74%) | 255 (70%) | |
| Unemployed/Other | 12 (11%) | 13 (10%) | 10 (8%) | 35 (10% | |
| Missing | 0 | 2 | 1 | 3 | |
| Time since Diagnosis (in years) | 0.791 | ||||
| Median | 2.57 | 1.99 | 2.60 | 2.42 | |
| Mean | 3.46 | 3.21 | 3.93 | 3.53 | |
| Range | (0.01 – 18.45) | (0.02 – 17.06) | (0.02 – 19.82) | (0.01 – 19.82) | |
| Missing | 6 | 7 | 9 | 22 |
1
Kruskal Wallis
2
Chi-Square
ECOG=Eastern Cooperative Oncology Group; GED=General Education Development
Note: Variables where complete data is not available have the frequency of patients with missing data provided. Variables with complete data are provided without the missing category.